Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Change in Account Payables (2020 - 2026)

Barinthus Biotherapeutics filings provide 7 years of Change in Account Payables readings, the most recent being $644000.0 for Q1 2026.

  • On a quarterly basis, Change in Account Payables rose 155.76% to $644000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$403000.0, a 250.94% decrease, with the full-year FY2025 number at -$2.2 million, down 345.21% from a year prior.
  • Change in Account Payables hit $644000.0 in Q1 2026 for Barinthus Biotherapeutics, up from -$348000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.3 million in Q3 2023 to a low of -$3.8 million in Q4 2023.
  • Median Change in Account Payables over the past 5 years was -$348000.0 (2025), compared with a mean of -$170470.6.
  • Biggest five-year swings in Change in Account Payables: soared 975.44% in 2022 and later plummeted 480.26% in 2023.
  • Barinthus Biotherapeutics' Change in Account Payables stood at $998000.0 in 2022, then plummeted by 480.26% to -$3.8 million in 2023, then soared by 87.88% to -$460000.0 in 2024, then rose by 24.35% to -$348000.0 in 2025, then soared by 285.06% to $644000.0 in 2026.
  • The last three reported values for Change in Account Payables were $644000.0 (Q1 2026), -$348000.0 (Q4 2025), and -$1.0 million (Q3 2025) per Business Quant data.